| 2XXD |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-JFH1 NS5B polymerase structure at 1.9 angstrom |
21209117 |
1.88 Å |
RNAP |
HCV RNAP (NS5B) |
PO4 [ PHOSPHATE ION ] |
| 2XYM |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-JFH1 NS5B T385A mutant |
21209117 |
1.77 Å |
RNAP |
HCV RNAP (NS5B) |
PO4 [ PHOSPHATE ION ] |
| 3I5K |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the NS5B polymerase from hepatitis C virus (HCV) strain JFH1 |
19740982 |
2.20 Å |
RNAP |
HCV RNAP (NS5B) |
PO4 [ PHOSPHATE ION ] |
| 4AEP |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-JFH1 NS5B polymerase structure at 1.8 angstrom |
22532694 |
1.80 Å |
RNAP |
HCV RNAP (NS5B) |
PO4 [ PHOSPHATE ION ] |
| 4AEX |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-JFH1 NS5B polymerase structure at 2.4 angstrom in a primitive orthorhombic space group |
22532694 |
2.41 Å |
RNAP |
HCV RNAP (NS5B) |
PO4 [ PHOSPHATE ION ] |
| 4E+076 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Apo crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with beta hairpin loop deletion |
22496223 |
2.50 Å |
RNAP |
HCV RNAP (NS5B) |
SO4 [SULFATE ION], EDO[ 1,2-ETHANEDIOL ] |
| 4E+078 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of a product state assembly of HCV NS5B genotype 2A JFH-1 Isolate with beta hairpin loop deletion bound to primer-template RNA with 3'-dG |
22496223 |
2.90 Å |
RNAP |
HCV RNAP (NS5B) |
|
| 4E7A |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of a product state assembly of HCV NS5B genotype 2A JFH-1 Isolate with beta hairpin deletion bound to primer-template RNA with a 2',3'-dDC |
22496223 |
3.00 Å |
RNAP |
HCV RNAP (NS5B) |
|
| 4OBC |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV polymerase NS5B genotype 2A JFH-1 Isolate with the S15G, C223H, V321I resistance mutations against the guanosine analog GS-0938 (PSI-3529238) |
25182647 |
2.50 Å |
RNAP |
HCV RNAP (NS5B) |
PG6[ 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE , MES[ 2-(N-MORPHOLINO)-ETHANESULFONIC ACID ], GOL, CL |
| 4WT9 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Apo crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with E86Q E87Q S15G C223H V321I and DELTA8 mutations |
25678663 |
2.50 Å |
RNAP |
HCV RNAP (NS5B) |
PG6[ 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE , EPE[4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID], CL |
| 4WTA |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations and DELTA8 beta hairpin loop deletion in complex with UDP,Mn2+ and symmetrical primer template 5'-CAAAAUUU |
25678663 |
2.80 Å |
RNAP |
HCV RNAP (NS5B) |
UDP[ URIDINE-5'-DIPHOSPHATE ], MN, CL |
| 4WTC |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations and delta8 beta hairpin loop deletion in complex with CDP,Mn2+ and symmetrical primer template 5'-AGAAAUUU |
25678663 |
2.75 Å |
RNAP |
HCV RNAP (NS5B) |
CDP[ CYTIDINE-5'-DIPHOSPHATE ], MN, CL |
| 4WTD |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations and delta8 beta hairpin loop deletion in complex with ADP,Mn2+ and symmetrical primer template 5'-AUAAAUUU |
25678663 |
2.70 Å |
RNAP |
HCV RNAP (NS5B) |
ADP[ ADENOSINE-5'-DIPHOSPHATE ], MN, CL |
| 4WTE |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations and delta8 beta hairpin loop deletion in complex with GDP,Mn2+ and symmetrical primer template 5'-ACAAAUUU |
25678663 |
2.90 Å |
RNAP |
HCV RNAP (NS5B) |
GDP[ GUANOSINE-5'-DIPHOSPHATE ], MN, CL |
| 4WTF |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations and delta8 beta hairpin loop deletion in complex with GS-639475,Mn2+ and symmetrical primer template 5'-CAAAAUUU |
25678663 |
2.65 Å |
RNAP |
HCV RNAP (NS5B) |
5GS[ 2'-C-methyluridine 5'-(trihydrogen diphosphate) ], MN, CL |
| 4WTG |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations and delta8 beta hairpin loop deletion in complex with sofosbuvir diphosphate GS-607596,Mn2+ and symmetrical primer template 5'-CAAAAUUU |
25678663 |
2.90 Å |
RNAP |
HCV RNAP (NS5B) |
6GS[ 2'-deoxy-2'-fluoro-2'-methyluridine 5'-(trihydrogen diphosphate) ], MN, CL |
| 4WTI |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations in complex with RNA template 5'-acgg, RNA primer 5'-pcc,Mn2+, and GDP |
25678663 |
2.80 Å |
RNAP |
HCV RNAP (NS5B) |
GDP[ GUANOSINE-5'-DIPHOSPHATE ], B3P[ 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL ],MN, CL |
| 4WTJ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations in complex with RNA template 5'-aucc, RNA primer 5'-pgg,Mn2+, and ADP |
25678663 |
2.20 Å |
RNAP |
HCV RNAP (NS5B) |
ADP[ ADENOSINE-5'-DIPHOSPHATE ], PG6[ 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE ], B3P[ 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL ], MN, CL |
| 4WTL |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations in complex with RNA template 5'-uacc, RNA primer 5'-pgg,Mn2+, and UDP |
25678663 |
2.00 Å |
RNAP |
HCV RNAP (NS5B) |
UDP[ URIDINE-5'-DIPHOSPHATE ], PG6[ 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE , B3P[ 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL ], MN, CL |
| 4WTK |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations in complex with RNA template 5'-agcc, RNA primer 5'-pgg,Mn2+, and CDP |
25678663 |
2.50 Å |
RNAP |
HCV RNAP (NS5B) |
CDP[ CYTIDINE-5'-DIPHOSPHATE ] ,PG6[ 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE , B3P[ 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL ], MN, CL |
| 4WTM |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B genotype 2A JFH-1 Isolate with S15G E86Q E87Q C223H V321I mutations in complex with RNA template 5'-uagg, RNA primer 5'-pcc,Mn2+, and UDP |
25678663 |
2.15 Å |
RNAP |
HCV RNAP (NS5B) |
UDP[ URIDINE-5'-DIPHOSPHATE ], MN, CL |
| 5TWM |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus genotype 2A strain JFH1 l30s NS5B RNAP in complex with 5-[3-(tert-butylcarbamoyl)phenyl]-6-(ethylamino)-2-(4-fluorophenyl)-N-methylfuro[2,3-b]pyridine-3-carboxamide |
30108798 |
1.97 Å |
RNAP |
HCV RNAP (NS5B) |
7NG[ 5-[3-(tert-butylcarbamoyl)phenyl]-6-(ethylamino)-2-(4-fluorophenyl)-N-methylfuro[2,3-b]pyridine-3-carboxamide ], PE5[ 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL], PG4[TETRAETHYLENE GLYCOL ], SO4 |
| 1C2P |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus NS5B RNAP |
10504728 |
1.90 Å |
RNAP |
RNAP (NS5B) |
|
| 1CSJ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the RNAP of hepatitis C virus |
10557268 |
2.80 Å |
RNAP |
RNAP (NS5B) |
|
| 1GX5 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus RNAP in complex with GTP andMn2+ |
11884572 |
1.70 Å |
RNAP |
RNAP (NS5B) |
GTP[ Guanosine-5'-Triphosphate ], MN |
| 1GX6 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus RNAP in complex with UTP andMn2+ |
11884572 |
1.85 Å |
RNAP |
RNAP (NS5B) |
UTP[ URIDINE 5'-TRIPHOSPHATE ], MN |
| 1NHU |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus RNAP in complex with non-nucleoside analogue inhibitor |
12509436 |
2.00 Å |
RNAP |
RNAP (NS5B) |
153[ (2S)-2-[(2,4-DICHLORO-BENZOYL)-(3-TRIFLUOROMETHYL-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID ] |
| 1NHV |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus RNAP in complex with non-nucleoside analogue inhibitor |
12509436 |
2.90 Å |
RNAP |
RNAP (NS5B) |
154[(2S)-2-[(5-BENZOFURAN-2-YL-THIOPHEN-2-YLMETHYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID] |
| 1OS5 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B RNAP complexed with a novel non-competitive inhibitor |
12805457 |
2.20 Å |
RNAP |
RNAP (NS5B) |
NH1[ 3-(4-AMINO-2-TERT-BUTYL-5-METHYL-PHENYLSULFANYL)-6-CYCLOPENTYL-4-HYDROXY-6-[2-(4-HYDROXY-PHENYL)-ETHYL]-5,6-DIHYDRO-PYRAN-2-ONE ] |
| 1QUV |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the RNA directed RNAP of hepatitis C virus |
10574802 |
2.50 Å |
RNAP |
RNAP (NS5B) |
|
| 2AWZ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus NS5B RNAP in complex with a covalent inhibitor (5H) |
16451069 |
2.15 Å |
RNAP |
RNAP (NS5B) |
5H[ 5R-(4-BROMOPHENYLMETHYL)-3-(BENZENESULFONYLAMINO)-4-OXO-2-THIONOTHIAZOLIDINE ] , SO4 |
| 2AX0 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus NS5B RNAP in complex with a covalent inhibitor (5X) |
16451069 |
2.00 Å |
RNAP |
RNAP (NS5B) |
5X[ 5R-(2E-METHYL-3-PHENYL-ALLYL)-3-(BENZENESULFONYLAMINO)-4-OXO-2-THIONOTHIAZOLIDINE ] , SO4 |
| 2AX1 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus NS5B RNAP in complex with a covalent inhibitor (5EE) |
16451069 |
2.10 Å |
RNAP |
RNAP (NS5B) |
5EE[ 5R-(3,4-DICHLOROPHENYLMETHYL)-3-(2-THIOPHENESULFONYLAMINO)-4-OXO-2-THIONOTHIAZOLIDINE ] , SO4 |
| 2BRK |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus polymerase in complex with an allosteric inhibitor (compound 1) |
15955819 |
2.30 Å |
RNAP |
RNAP (NS5B) |
CMF[ 3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID ] , MN |
| 2BRL |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus polymerase in complex with an allosteric inhibitor (compound 2) |
15955819 |
2.40 Å |
RNAP |
RNAP (NS5B) |
POO[ 3-CYCLOHEXYL-1-(2-{METHYL[(1-METHYLPIPERIDIN-3-YL)METHYL]AMINO}-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID ], MN |
| 2DXS |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B RNAP complexed with a tetracyclic inhibitor |
17125247 |
2.20 Å |
RNAP |
RNAP (NS5B) |
JTP[ N-[(13-CYCLOHEXYL-6,7-DIHYDROINDOLO[1,2-D][1,4]BENZOXAZEPIN-10-YL)CARBONYL]-2-METHYL-L-ALANINE ] |
| 2GIQ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus RNAP NS5B with NNI-2 inhibitor |
16731953 |
1.65 Å |
RNAP |
RNAP (NS5B) |
NN2[ 1-(2-CYCLOPROPYLETHYL)-3-(1,1-DIOXIDO-2H-1,2,4-BENZOTHIADIAZIN-3-YL)-6-FLUORO-4-HYDROXYQUINOLIN-2(1H)-ONE ] |
| 2GIR |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus RNAP NS5B with NNI-1 inhibitor |
16731953 |
1.90 Å |
RNAP |
RNAP (NS5B) |
NN3[ 3-{ISOPROPYL[(TRANS-4-METHYLCYCLOHEXYL)CARBONYL]AMINO}-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID ] |
| 2HAI |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B RNAP in complex with novel Classification of dihydropyrone-containing inhibitor. |
16824756 |
1.58 Å |
RNAP |
RNAP (NS5B) |
PFI[ (6S)-6-CYCLOPENTYL-6-[2-(3-FLUORO-4-ISOPROPOXYPHENYL)ETHYL]-4-HYDROXY-5,6-DIHYDRO-2H-PYRAN-2-ONE ] |
| 2HWH |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B allosteric inhibitor complex |
16934455 |
2.30 Å |
RNAP |
RNAP (NS5B) |
RNA[ 4-METHYL-N-{(5E)-5-[(5-METHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}BENZENESULFONAMIDE ] |
| 2HWI |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B allosteric inhibitor complex |
16934455 |
2.00 Å |
RNAP |
RNAP (NS5B) |
VRX[ (2S)-({(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}AMINO)(4-FLUOROPHENYL)ACETIC ACID ] |
| 2I1R |
XRD |
Virus |
Hepatitis C virus(HCV) |
Novel thiazolones as HCV NS5B polymerase inhibitors: further designs, synthesis, sar and X-ray complex structure |
17049849 |
2.20 Å |
RNAP |
RNAP (NS5B) |
VXR[ (5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-2-{[(S)-(4-FLUOROPHENYL)(1H-TETRAZOL-5-YL)METHYL]AMINO}-1,3-THIAZOL-4(5H)-ONE ] |
| 2JC0 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus polymerase in complex with inhibitor SB655264 |
17269759 |
2.20 Å |
RNAP |
RNAP (NS5B) |
699[ (2S,4S,5R)-2-ISOBUTYL-5-(2-THIENYL)-1-[4-(TRIFLUOROMETHYL)BENZOYL]PYRROLIDINE-2,4-DICARBOXYLIC ACID ] |
| 2JC1 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus polymerase in complex with inhibitor SB698223 |
17269759 |
2.00 Å |
RNAP |
RNAP (NS5B) |
698[ (2S,4S,5R)-1-(4-TERT-BUTYLBENZOYL)-2-ISOBUTYL-5-(1,3-THIAZOL-2-YL)PYRROLIDINE-2,4-DICARBOXYLIC ACID ] |
| 2O5D |
XRD |
Virus |
Hepatitis C virus(HCV) |
Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study |
17276060 |
2.20 Å |
RNAP |
RNAP (NS5B) |
VR1[ (2S)-2-({(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}AMINO)-2-(4-FLUOROPHENYL)-N-[(4-NITROPHENYL)SULFONYL]ACETAMIDE ] |
| 2WCX |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus NS5B polymerase in complex with thienopyrrole-based finger-loop inhibitors |
19672916 |
2.00 Å |
RNAP |
RNAP (NS5B) |
VGC[ 6-CYCLOHEXYL-4-METHYL-5-PHENYL-4H-THIENO[3,2-B]PYRROLE-2-CARBOXYLIC ACID ] |
| 2WHO |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus NS5B polymerase from 1b genotype in complex with a non-nucleoside inhibitor |
19877603 |
2.00 Å |
RNAP |
RNAP (NS5B) |
VGI[ 2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino]-1h-benzo[de]isoquinoline-1,3(2h)-dione ] , MN |
| 2WRM |
XRD |
Virus |
Hepatitis C virus(HCV) |
Identification of novel allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain (site II) by structure-based design |
To be published. |
1.95 Å |
RNAP |
RNAP (NS5B) |
QQ3[ (3R)-3-(4-METHYL-1,3-DIOXO-1,3-DIHYDRO-2H-PYRROLO[3,4-C]QUINOLIN-2-YL)HEXANOIC ACID ] |
| 2XWY |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structure of MK-3281, a potent non-nucleoside finger-loop inhibitor, in complex with the hepatitis C virus NS5B polymerase |
21141896 |
2.53 Å |
RNAP |
RNAP (NS5B) |
IB8[ (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl)amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid ] , MN |
| 2ZKU |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structure of hepatitis C virus NS5B polymerase in a new crystal form |
To be published. |
1.95 Å |
RNAP |
RNAP (NS5B) |
GOL, ACY[ACETIC ACID] |
| 3BR9 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18242088 |
2.30 Å |
RNAP |
RNAP (NS5B) |
DEY[ (2R)-2-({3-[5-hydroxy-2-(3-methylbutyl)-3-oxo-6-thiophen-2-yl-2,3-dihydropyridazin-4-yl]-1,1-dioxido-2H-1,2,4-benzothia diazin-7-yl}oxy)propanamide ] |
| 3BSA |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18242088 |
2.30 Å |
RNAP |
RNAP (NS5B) |
1PD[ 2-({3-[5-hydroxy-2-(3-methylbutyl)-3-oxo-6-(1,3-thiazol-5-yl)-2,3-dihydropyridazin-4-yl]-1,1-dioxido-2H-1,2,4-benzothia diazin-7-yl}oxy)acetamide ] |
| 3BSC |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18242088 |
2.65 Å |
RNAP |
RNAP (NS5B) |
2PD[ 5-hydroxy-4-(7-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-(3-methylbutyl)-6-phenylpyridazin-3(2H)-one ] |
| 3CDE |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18457949 |
2.10 Å |
RNAP |
RNAP (NS5B) |
N3H[ N-{3-[5-hydroxy-2-(3-methylbutyl)-3-oxo-6-thiophen-2-yl-2,3-dihydropyridazin-4-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide ] |
| 3CIZ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus RNAP NS5B in complex with small molecule fragments |
18400495 |
1.87 Å |
RNAP |
RNAP (NS5B) |
SX1[ 2-amino-5-bromobenzoic acid ] , ZN |
| 3CJ0 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus RNAP NS5B in complex with small molecule fragments |
18400495 |
1.90 Å |
RNAP |
RNAP (NS5B) |
SX2[ 4-[(5-bromopyridin-2-yl)amino]-4-oxobutanoic acid ] |
| 3CJ2 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus RNAP NS5B in complex with optimized small molecule fragments |
18400495 |
1.75 Å |
RNAP |
RNAP (NS5B) |
SX3[ 4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}aniline ] , NI |
| 3CJ3 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus RNAP NS5B in complex with optimized small molecule fragments |
18400495 |
1.87 Å |
RNAP |
RNAP (NS5B) |
SX4[ 4-bromo-2-{[(2R)-2-(2-chlorobenzyl)pyrrolidin-1-yl]carbonyl}aniline ] , NI |
| 3CJ4 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus RNAP NS5B in complex with optimized small molecule fragments |
18400495 |
2.07 Å |
RNAP |
RNAP (NS5B) |
SX5[ 4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid ] , NI |
| 3CJ5 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of hepatitis C virus RNAP NS5B in complex with optimized small molecule fragments |
18400495 |
1.92 Å |
RNAP |
RNAP (NS5B) |
SX6[ N-(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)-4-morpholin-4-yl-4-oxobutanamide ] |
| 3CO9 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18487044 |
2.10 Å |
RNAP |
RNAP (NS5B) |
3MS[ N-{3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7 -yl}methanesulfonamide ] |
| 3CVK |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18722768 |
2.31 Å |
RNAP |
RNAP (NS5B) |
N34[ N-{3-[1-(3,3-Dimethyl-butyl)-4-hydroxy-2-oxo-1,2,4a,5,6,7-hexahydro-pyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxo-1,2-dihydro -1lambda6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide ] |
| 3CWJ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18662878 |
2.40 Å |
RNAP |
RNAP (NS5B) |
321[ N-{3-[5-hydroxy-2-(3-methylbutyl)-3-oxo-6-thiophen-2-yl-2,3-dihydropyridazin-4-yl]-1,1-dioxido-2H-1,4-benzothiazin-7-yl}methanesulfonamide ] |
| 3D28 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel benzisothiazole inhibitor |
18554907 |
2.30 Å |
RNAP |
RNAP (NS5B) |
B34[ (5S)-1-benzyl-3-(1,1-dioxido-1,2-benzisothiazol-3-yl)-4-hydroxy-5-(1-methylethyl)-1,5-dihydro-2H-pyrrol-2-one ] |
| 3D5M |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18554907 |
2.20 Å |
RNAP |
RNAP (NS5B) |
4MS[ N-({3-[(5S)-5-tert-butyl-1-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-1,1-dioxido-1,2-benzis othiazol-7-yl}methyl)methanesulfonamide ] |
| 3E+051 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor |
18796353 |
1.90 Å |
RNAP |
RNAP (NS5B) |
N35[ N-{3-[5-hydroxy-2-(3-methylbutyl)-3-oxo-6-pyrrolidin-1-yl-2,3-dihydropyridazin-4-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide ] |
| 3FQK |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B (BK 1-570) with HCV-796 inhibitor |
19246450 |
2.20 Å |
RNAP |
RNAP (NS5B) |
79Z[ 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide ] |
| 3FRZ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B RNAP in complex with PF868554 |
19209845 |
1.86 Å |
RNAP |
RNAP (NS5B) |
AG6[ N-[(benzyloxy)carbonyl]-L-alpha-glutamyl-N-[(1S)-4-oxo-4-phenyl-1-propylbut-2-en-1-yl]-L-phenylalaninamide ], AG0[ (6R)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-d |
| 3G86 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B (BK 1-570) with thiazine inhibitor |
19457662 |
2.20 Å |
RNAP |
RNAP (NS5B) |
T18[ N-{3-[6-fluoro-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]-1,1-dioxido-4H-1,4-benzothiazin-7-yl}methanesulfonamide), N-{3-[6-fluoro-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]-1,1-dioxido-4H-1,4-benzothiazin-7-yl}me |
| 3GYN |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel monocyclic dihydropyridinone inhibitor |
19796938 |
2.15 Å |
RNAP |
RNAP (NS5B) |
B42[ N-{3-[(5R)-1-cyclopentyl-4-hydroxy-5-methyl-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide ] |
| 3H2L |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with a novel bicyclic dihydro-pyridinone inhibitor |
19818610 |
1.90 Å |
RNAP |
RNAP (NS5B) |
YAK[ N-{3-[(4aR,7aS)-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-2,4a,5,6,7,7a-hexahydro-1H-cyclopenta[b]pyridin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide ] |
| 3IGV |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with a novel monocyclic dihydro-pyridinone inhibitor |
19796938 |
2.60 Å |
RNAP |
RNAP (NS5B) |
B80[ N-{3-[(6S)-6-ethyl-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide ] |
| 3MF5 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B (BK) with amide bioisostere thumb site inhibitor |
20584604 |
2.00 Å |
RNAP |
RNAP (NS5B) |
HJZ[ 3-[2-(trans-4-methylcyclohexyl)phenyl]-5-phenylthiophene-2-carboxylic acid ] , GOL |
| 3H59 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B with thiazine inhibitor 2 |
19700319 |
2.10 Å |
RNAP |
RNAP (NS5B) |
H59[ N-{3-[(5S)-5-(1,1-dimethylpropyl)-1-(4-fluoro-3-methylbenzyl)-4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-1,1-dioxido-4H-1,4-benzothiazin-7-yl}methanesulfonamide ] |
| 3H5S |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B with saccharin inhibitor |
19709881 |
2.00 Å |
RNAP |
RNAP (NS5B) |
H5S[ (5S)-5-tert-butyl-1-(4-fluoro-3-methylbenzyl)-4-hydroxy-3-[8-(methylsulfonyl)-1,1-dioxido-6,7,8,9-tetrahydroisothiazolo[4,5-h]isoquinolin-3-yl]-1,5-dihydro-2H-pyrrol-2-one ] |
| 3H5U |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B with saccharin inhibitor 1 |
19709881 |
1.95 Å |
RNAP |
RNAP (NS5B) |
H5U[ N-({3-[(5S)-5-tert-butyl-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-1,1-dioxido-1,2-benzisothiazol-7-yl}methyl)methanesulfonamide ] |
| 3H98 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B 1b with (1,1-dioxo-2h-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyrimidine derivative |
19500983 |
1.90 Å |
RNAP |
RNAP (NS5B) |
B5P[ N-{3-[5-hydroxy-8-(3-methylbutyl)-7-oxo-7,8-dihydroimidazo[1,2-a]pyrimidin-6-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide ] , GOL |
| 3UDL |
XRD |
Virus |
Hepatitis C virus(HCV) |
3-heterocyclyl quinolone bound to HCV NS5B |
21145235 |
2.17 Å |
RNAP |
RNAP (NS5B) |
KLI[ 3-(5-benzyl-1,2,4-oxadiazol-3-yl)-6-fluoro-1-[2-fluoro-4-(trifluoromethyl)benzyl]-7-(4-methylpiperazin-1-yl)quinolin-4(1H)-one ] |
| 3VQS |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B RNAP with a novel piperazine inhibitor |
22615294 |
1.90 Å |
RNAP |
RNAP (NS5B) |
JT1[ (2R)-4-(5-cyclopropyl[1,3]thiazolo[4,5-d]pyrimidin-2-yl)-N-[3-fluoro-4-(trifluoromethoxy)benzyl]-1-{[4-(trifluoromethyl)phenyl]sulfonyl}piperazine-2-carboxamide ] , CL |
| 4EO6 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase inhibitors: Tri-substituted acylhydrazines as tertiary amide bioisosteres |
22664130 |
1.79 Å |
RNAP |
RNAP (NS5B) |
0S2[ 5-(3,3-dimethylbut-1-yn-1-yl)-3-{[(trans-4-methylcyclohexyl)carbonyl](propan-2-yl)amino}thiophene-2-carboxylic acid ] |
| 4EO8 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase inhibitors: Tri-substituted acylhydrazines as tertiary amide bioisosteres |
22664130 |
1.80 Å |
RNAP |
RNAP (NS5B) |
0S3[ 5-(3,3-dimethylbut-1-yn-1-yl)-3-{2,2-dimethyl-1-[(trans-4-methylcyclohexyl)carbonyl]hydrazinyl}thiophene-2-carboxylic acid ] |
| 4IH5 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B (BK) with fragment-based compounds |
23509929 |
1.90 Å |
RNAP |
RNAP (NS5B) |
12R[ 4-(2-phenylhydrazinyl)-1H-pyrazolo[3,4-d]pyrimidine ] |
| 4IH6 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B (BK) with fragment-based compounds |
23509929 |
2.20 Å |
RNAP |
RNAP (NS5B) |
1EP[ (5S)-3-(4-tert-butylbenzyl)-5-(propan-2-yl)imidazolidine-2,4-dione ] |
| 4IH7 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B (BK) with fragment-based compounds |
23509929 |
2.30 Å |
RNAP |
RNAP (NS5B) |
1ER[ 3-(3-tert-butylphenyl)pyridin-2(1H)-one ] , ZN |
| 4KAI |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B GT1B N316 with GSK5852A |
23672667 |
2.30 Å |
RNAP |
RNAP (NS5B) |
1PV[ [4-({[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl](methylsulfonyl)amino}methyl)-2-fluorophenyl]boronic acid ] |
| 4KB7 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B GT1B N316Y with CMPD 32 |
23672667 |
1.85 Å |
RNAP |
RNAP (NS5B) |
690[ 5-cyclopropyl-2-(4-fluorophenyl)-6-[{2-[(3R)-1-hydroxy-1,3-dihydro-2,1-benzoxaborol-3-yl]ethyl}(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide ] |
| 4KBI |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B GT1B N316Y with CMPD 4 |
23672667 |
2.06 Å |
RNAP |
RNAP (NS5B) |
1C0[ 5-cyclopropyl-6-{[(7-fluoro-1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)methyl](methylsulfonyl)amino}-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide ] |
| 4KE5 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B GT1B N316Y with GSK5852 |
23672667 |
2.11 Å |
RNAP |
RNAP (NS5B) |
1PV[ [4-({[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl](methylsulfonyl)amino}methyl)-2-fluorophenyl]boronic acid ] |
| 4MIA |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B genotype 1b (BK) in complex with RG7109 |
24195700 |
2.80 Å |
RNAP |
RNAP (NS5B) |
28L[ N-{4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-2,5-dihydropyridin-3-yl)quinolin-3-yl]phenyl}methanesulfonamide ] , ZN |
| 4MIB |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B genotype 1b (BK) in complex with compound 48 |
24195700 |
2.30 Å |
RNAP |
RNAP (NS5B) |
28M[ N-({(3S)-1-[6-tert-butyl-5-methoxy-8-(2-oxo-1,2-dihydropyridin-3-yl)quinolin-3-yl]pyrrolidin-3-yl}methyl)methanesulfonamide ] , DMS[ DIMETHYL SULFOXIDE ] |
| 4MK7 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 2 (3-(3-tert-butyl-4-methoxyphenyl)pyridin-2(1h)-one) |
24069953 |
2.80 Å |
RNAP |
RNAP (NS5B) |
28O[ 3-(3-tert-butyl-4-methoxyphenyl)pyridin-2(1H)-one] , DMS[DIMETHYL SULFOXIDE ], MG |
| 4MK8 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 4 |
24069953 |
2.09 Å |
RNAP |
RNAP (NS5B) |
28Q[ N-(4-{2-[3-tert-butyl-2-methoxy-5-(2-oxo-1,2-dihydropyridin-3-yl)phenyl]ethyl}phenyl)methanesulfonamide ] , GOL, DMS[ DIMETHYL SULFOXIDE ] |
| 4MK9 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 12 |
24069953 |
2.05 Å |
RNAP |
RNAP (NS5B) |
28R[ N-{2-[3-tert-butyl-2-methoxy-5-(2-oxo-1,2-dihydropyridin-3-yl)phenyl]-1,3-benzoxazol-5-yl}methanesulfonamide ] , GOL |
| 4MKA |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 13 |
24069953 |
2.05 Å |
RNAP |
RNAP (NS5B) |
2AY[ N-{3-[3-tert-butyl-2-methoxy-5-(2-oxo-1,2-dihydropyridin-3-yl)phenyl]-1-oxo-1H-isochromen-7-yl}methanesulfonamide ] , GOL, DMS[ DIMETHYL SULFOXIDE ] |
| 4MKB |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 14 |
24069953 |
1.90 Å |
RNAP |
RNAP (NS5B) |
28V[ N-(4-{(E)-2-[3-tert-butyl-2-methoxy-5-(3-oxo-2,3-dihydropyridazin-4-yl)phenyl]ethenyl}phenyl)methanesulfonamide ] |
| 4TN2 |
XRD |
Virus |
Hepatitis C virus(HCV) |
NS5B in complex with lactam-thiophene carboxylic acids |
24986660 |
2.70 Å |
RNAP |
RNAP (NS5B) |
33J[ 3-[(2R)-2-cyclohexyl-5-oxopyrrolidin-1-yl]-5-phenylthiophene-2-carboxylic acid ] |
| 5W2E |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B RNAP in complex with non-nucleoside inhibitor MK-8876 |
28741898 |
2.80 Å |
RNAP |
RNAP (NS5B) |
9VY[ 2-(4-fluorophenyl)-5-(11-fluoro-6H-pyrido[2',3':5,6][1,3]oxazino[3,4-a]indol-2-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide ] |
| 6MVP |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B 1b N316 bound to compound 18 |
30763090 |
2.00 Å |
RNAP |
RNAP (NS5B) |
K4S[ (4-{[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl](methylsulfonyl)amino}phenyl)boronic acid ] |
| 1NB4 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HC-J4 RNAP apo-form |
12589751 |
2.00 Å |
RNAP |
RNAP (NS5B) |
|
| 1NB6 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HC-J4 RNAP complexed with UTP |
12589751 |
2.60 Å |
RNAP |
RNAP (NS5B) |
UTP[ URIDINE 5'-TRIPHOSPHATE ], MN |
| 1NB7 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HC-J4 RNAP complexed with short RNA template strand |
12589751 |
2.90 Å |
RNAP |
RNAP (NS5B) |
MN |
| 2XHU |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-I4 NS5B polymerase orthorhombic crystal form |
20729191 |
2.29 Å |
RNAP |
RNAP (NS5B) |
SO4 |
| 2XHV |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-I4 NS5B polymerase point mutant orthorhombic crystal form |
20729191 |
1.90 Å |
RNAP |
RNAP (NS5B) |
SO4, MG |
| 2XHW |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-I4 NS5B polymerase trigonal crystal form |
20729191 |
2.66 Å |
RNAP |
RNAP (NS5B) |
|
| 2YOJ |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase complexed with pyridonylindole compound |
24900812 |
1.76 Å |
RNAP |
RNAP (NS5B) |
8Y6[ 4-fluoranyl-6-[(7-fluoranyl-4-oxidanylidene-3H-quinazolin-6-yl)methyl]-8-(2-oxidanylidene-1H-pyridin-3-yl)furo[2,3-e]indole-7-carboxylic acid] , PO4[PHOSPHATE ION ] |
| 3CSO |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV polymerase in complex with a 1,5 benzodiazepine inhibitor |
18852280 |
2.71 Å |
RNAP |
RNAP (NS5B) |
XNI[ (11S)-10-acetyl-11-[4-(benzyloxy)-3-chlorophenyl]-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one ] |
| 3GNV |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase in complex with 1,5 benzodiazepine inhibitor 1b |
19507864 |
2.75 Å |
RNAP |
RNAP (NS5B) |
XNZ[ (11R)-10-acetyl-11-[4-(benzyloxy)-2-chlorophenyl]-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one ] , GOL |
| 3GNW |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase in complex with 1,5 benzodiazepine inhibitor 4c |
19507864 |
2.39 Å |
RNAP |
RNAP (NS5B) |
XNC[ (11S)-11-[4-(benzyloxy)-2-fluorophenyl]-3,3-dimethyl-10-[(6-methylpyridin-2-yl)carbonyl]-2,3,4,5,10,11-hexahydrothiopyrano[3,2-b][1,5]benzodiazepin-6-ol 1,1-dioxide ] , CL |
| 3GOL |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase in complex with 1,5 benzodiazepine inhibitor (r)-11d |
19342234 |
2.85 Å |
RNAP |
RNAP (NS5B) |
XND[ (11R)-10-acetyl-11-(2,4-dichlorophenyl)-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one ] , MG |
| 3HKY |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase genotype 1b in complex with 1,5 benzodiazepine 6 |
20071590 |
1.90 Å |
RNAP |
RNAP (NS5B) |
IX6[ (11S)-10-[(2,5-dimethyl-1,3-oxazol-4-yl)carbonyl]-11-{2-fluoro-4-[(2-methylprop-2-en-1-yl)oxy]phenyl}-3,3-dimethyl-2,3,4,5,10,11-hexahydrothiopyrano[3,2-b][1,5]benzodiazepin-6-ol 1,1-dioxide ] , SO4, CL |
| 3LKH |
XRD |
Virus |
Hepatitis C virus(HCV) |
Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 6-fluoro-N-[2-hydroxy-1(s)-benzamides |
20219368 |
2.05 Å |
RNAP |
RNAP (NS5B) |
LT6[ 2-(2-{[(1S)-1-benzyl-2-hydroxyethyl]amino}-2-oxoethoxy)-N-butyl-6-fluoro-N-methylbenzamide ] |
| 3MWV |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase |
20942454 |
2.20 Å |
RNAP |
RNAP (NS5B) |
|
| 3MWW |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase |
20942454 |
2.80 Å |
RNAP |
RNAP (NS5B) |
BIW[ 1-[2-(4-carboxypiperidin-1-yl)-2-oxoethyl]-3-cyclohexyl-2-furan-3-yl-1H-indole-6-carboxylic acid ] , SO4 |
| 3SKA |
XRD |
Virus |
Hepatitis C virus(HCV) |
I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2- carboxylic acids with c3-heterocycles |
21840715 |
1.73 Å |
RNAP |
RNAP (NS5B) |
053[ 1-[(2-aminopyridin-4-yl)methyl]-3-(2-oxo-1,2-dihydropyridin-3-yl)-5-(trifluoromethyl)-1H-indole-2-carboxylic acid ] , PO4 |
| 3SKE |
XRD |
Virus |
Hepatitis C virus(HCV) |
I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2- carboxylic acids with c3-heterocycles |
21840715 |
1.97 Å |
RNAP |
RNAP (NS5B) |
054[ 1-[(2-aminopyridin-4-yl)methyl]-3-(2,4-dioxo-1,2-dihydrothieno[3,4-d]pyrimidin-3(4H)-yl)-5-(trifluoromethyl)-1H-indole-2-carboxylic acid ] , PO4 |
| 3SKH |
XRD |
Virus |
Hepatitis C virus(HCV) |
I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2- carboxylic acids with c3-heterocycles |
21840715 |
2.50 Å |
RNAP |
RNAP (NS5B) |
058[ 1-benzyl-5-chloro-3-(2-fluorophenyl)-1H-indole-2-carboxylic acid ] |
| 3TYQ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Sar development and discovery of potent indole-based inhibitors of the hepatitis C virus NS5B polymerase |
22247956 |
1.60 Å |
RNAP |
RNAP (NS5B) |
HI4[ 5-ethyl-1-(2-fluoro-5-nitrobenzyl)-3-(2-oxo-1,2-dihydropyridin-3-yl)-1H-indole-2-carboxylic acid ] , PO4 |
| 3TYV |
XRD |
Virus |
Hepatitis C virus(HCV) |
Sar development and discovery of potent indole-based inhibitors of the hepatitis C virus NS5B polymerase |
22148957 |
1.65 Å |
RNAP |
RNAP (NS5B) |
HI3[ N-(cyclopropylsulfonyl)-1-(2,5-difluorobenzyl)-6-fluoro-5-methyl-3-(2-oxo-1,2-dihydropyridin-3-yl)-1H-indole-2-carboxamide ] , PO4 |
| 3U4O |
XRD |
Virus |
Hepatitis C virus(HCV) |
Novel HCV NS5B polymerase inhibitors: discovery of indole c2 acyl sulfonamides |
22104146 |
1.77 Å |
RNAP |
RNAP (NS5B) |
08E[ 1-[(2-aminopyridin-4-yl)methyl]-5-chloro-3-(2-oxo-1,2-dihydropyridin-3-yl)-1H-indole-2-carboxylic acid ] , PO4 |
| 3U4R |
XRD |
Virus |
Hepatitis C virus(HCV) |
Novel HCV NS5B polymerase inhibitors: discovery of indole c2 acyl sulfonamides |
22104146 |
2.00 Å |
RNAP |
RNAP (NS5B) |
08F[ 1-[(2-aminopyridin-4-yl)methyl]-5-chloro-N-({3-[(methylsulfonyl)amino]phenyl}sulfonyl)-3-(2-oxo-1,2-dihydropyridin-3-yl)-1H-indole-2-carboxamide ] |
| 3UPH |
XRD |
Virus |
Hepatitis C virus(HCV) |
Synthesis of novel 4,5-dihydrofurano indoles and their evaluation as HCV NS5B polymerase inhibitors |
22220815 |
2.00 Å |
RNAP |
RNAP (NS5B) |
0C1[ 6-(2,5-difluorobenzyl)-N-(methylsulfonyl)-8-(2-oxo-1,2-dihydropyridin-3-yl)-3,6-dihydro-2H-furo[2,3-e]indole-7-carboxamide ] , PO4 |
| 3UPI |
XRD |
Virus |
Hepatitis C virus(HCV) |
Synthesis of novel 4,5-dihydrofurano indoles and their evaluation as HCV NS5B polymerase inhibitors |
22220815 |
2.00 Å |
RNAP |
RNAP (NS5B) |
0C2[ (3S)-6-(2,5-difluorobenzyl)-3-methyl-N-(methylsulfonyl)-8-(2-oxo-1,2-dihydropyridin-3-yl)-3,6-dihydro-2H-furo[2,3-e]indole-7-carboxamide ] , PO4 |
| 4DRU |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B in complex with macrocyclic indole inhibitor |
22473861 |
2.10 Å |
RNAP |
RNAP (NS5B) |
0LN[ 13-cyclohexyl-3-methoxy-17,22-dimethyl-7H-10,6-(methanoiminothioiminobutanoiminomethano)indolo[2,1-a][2]benzazepine-14,23-dione 16,16-dioxide ] , SO4, GOL |
| 4EAW |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B in complex with Idx375 |
To be published. |
2.00 Å |
RNAP |
RNAP (NS5B) |
0NQ[ N-{(1S)-3-[(5S)-5-tert-butyl-1-(3,3-dimethylbutyl)-4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-1-ethoxy-1-oxido-1,4-dihydro-2,4,1-benzodiazaphosphinin-7-yl}methanesulfonamide ] , PEG[ DI(HYDROXYETHYL)ETHER ], SO4, EDO[1,2-ETHANEDIOL] |
| 4GMC |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with a thumb inhibitor |
|
2.70 Å |
RNAP |
RNAP (NS5B) |
1BI[ 3-cyclohexyl-2-(furan-3-yl)-1-[2-(morpholin-4-yl)-2-oxoethyl]-N-(phenylsulfonyl)-1H-indole-6-carboxamide ] , SO4 |
| 4IZ0 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with 2,4,5-trichloro-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide |
23545108 |
2.22 Å |
RNAP |
RNAP (NS5B) |
2BI[ 2,4,5-trichloro-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide ] |
| 4J02 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with [(1r)-5,8-dichloro-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid |
23545108 |
2.00 Å |
RNAP |
RNAP (NS5B) |
1JE[ [(1R)-5,8-dichloro-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid ] , SO4 , NA |
| 4J04 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with 4-chloro-2-{[(2,4,5-trichlorophenyl)sulfonyl]amino}benzoic acid |
23545108 |
2.00 Å |
RNAP |
RNAP (NS5B) |
1JF[ 4-chloro-2-{[(2,4,5-trichlorophenyl)sulfonyl]amino}benzoic acid ] , MN |
| 4J06 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with 2-{[(5-bromothiophen-2-yl)sulfonyl]amino}-4-chlorobenzoic acid |
23545108 |
2.00 Å |
RNAP |
RNAP (NS5B) |
1JG[ 2-{[(5-bromothiophen-2-yl)sulfonyl]amino}-4-chlorobenzoic acid ] |
| 4J08 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with 2-{[(4-methylphenyl)sulfonyl]amino}-5-phenoxybenzoic acid |
23545108 |
2.10 Å |
RNAP |
RNAP (NS5B) |
1JH[ 2-{[(4-methylphenyl)sulfonyl]amino}-5-phenoxybenzoic acid ] |
| 4J0A |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with 2-{[(4-methylphenyl)sulfonyl]amino}-4-phenoxybenzoic acid |
23545108 |
2.40 Å |
RNAP |
RNAP (NS5B) |
1JL[ 2-{[(4-methylphenyl)sulfonyl]amino}-4-phenoxybenzoic acid ] |
| 4JJS |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 2 |
23768906 |
2.20 Å |
RNAP |
RNAP (NS5B) |
1M9[ 2-{[(trans-4-methylcyclohexyl)carbonyl](propan-2-yl)amino}-5-[2-(trifluoromethyl)phenoxy]benzoic acid ] , MG |
| 4JJU |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 29 |
23768906 |
1.91 Å |
RNAP |
RNAP (NS5B) |
1MB[ 1-(2,4-difluorobenzyl)-6-{[3-(trifluoromethyl)pyridin-2-yl]oxy}quinazolin-4(1H)-one ] , GOL, MG |
| 4JTW |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with coupound 1 |
23773186 |
3.00 Å |
RNAP |
RNAP (NS5B) |
1NU[ 1-(2,4,6-trifluorobenzyl)-6-[2-(trifluoromethyl)phenoxy]quinazolin-4(1H)-one ] , GOL, MG |
| 4JTY |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase with compound 2 |
23773186 |
2.60 Å |
RNAP |
RNAP (NS5B) |
1NV[ 3-{[4-oxo-1-(2,4,6-trifluorobenzyl)-1,4-dihydroquinazolin-6-yl]oxy}-2-(trifluoromethyl)benzamide ] , GOL, MG |
| 4JTZ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 4 |
23773186 |
2.80 Å |
RNAP |
RNAP (NS5B) |
1NW[ 3-{[4-oxo-1-(2,4,6-trifluorobenzyl)-1,4-dihydroquinazolin-6-yl]oxy}-N-(pyridin-3-yl)-2-(trifluoromethyl)benzamide ] , GOL, MG |
| 4JU1 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 6 |
23773186 |
2.90 Å |
RNAP |
RNAP (NS5B) |
1NZ[ 6-[3-([1,3]oxazolo[4,5-b]pyridin-2-yl)-2-(trifluoromethyl)phenoxy]-1-(2,4,6-trifluorobenzyl)quinazolin-4(1H)-one ] , GOL, MG |
| 4JU2 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 12 |
23773186 |
2.70 Å |
RNAP |
RNAP (NS5B) |
1O0 [6-[3-(pyridin-2-yl)-2-(trifluoromethyl)phenoxy]-1-(2,4,6-trifluorobenzyl)quinazolin-4(1H)-one ] , GOL, MG |
| 4JU3 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 8 |
24176401 |
2.00 Å |
RNAP |
RNAP (NS5B) |
1O1[ 5-(4-carboxyphenoxy)-2-{[(4-methylphenyl)sulfonyl]amino}benzoic acid ] , MG |
| 4JU4 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 22 |
24176401 |
2.40 Å |
RNAP |
RNAP (NS5B) |
1O3[ 2-{[(4-bromo-2-fluorophenyl)sulfonyl]amino}-5-phenoxybenzoic acid ] , MG |
| 4JU6 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 24 |
24176401 |
2.20 Å |
RNAP |
RNAP (NS5B) |
1O6[ 2-{[(trans-4-methylcyclohexyl)carbonyl](propan-2-yl)amino}-5-phenoxybenzoic acid ] , MG |
| 4JU7 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 24 |
24176401 |
2.20 Å |
RNAP |
RNAP (NS5B) |
1O6[ 2-{[(trans-4-methylcyclohexyl)carbonyl](propan-2-yl)amino}-5-phenoxybenzoic acid ] , MG |
| 4JVQ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 9 |
24024973 |
2.40 Å |
RNAP |
RNAP (NS5B) |
1ML[ 5-{4-[(4-methoxybenzoyl)amino]phenoxy}-2-{[(trans-4-methylcyclohexyl)carbonyl](propan-2-yl)amino}benzoic acid ] , GOL, MG |
| 4JY0 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 3 |
To be published. |
2.20 Å |
RNAP |
RNAP (NS5B) |
1O9[C [auth A], D [auth B] (4S,5R)-1-(4-tert-butylbenzoyl)-2-(2-methylpropyl)-4-pyrazin-2-yl-5-(1,3-thiazol-2-yl)-L-proline ] |
| 4JY1 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of HCV NS5B polymerase in complex with compound 5 |
To be published. |
2.60 Å |
RNAP |
RNAP (NS5B) |
NN3[ 3-{ISOPROPYL[(TRANS-4-METHYLCYCLOHEXYL)CARBONYL]AMINO}-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID ] |
| 4MZ4 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Discovery of an Irreversible HCV NS5B polymerase inhibitor |
24252545 |
1.63 Å |
RNAP |
RNAP (NS5B) |
2F3[ 1-[(2-chloroquinolin-3-yl)methyl]-6-fluoro-5-methyl-3-(2-oxo-1,2-dihydropyridin-3-yl)-1H-indole-2-carboxylic acid ] , PO4 |
| 4OOW |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase with a fragment of quercetagetin |
25053847 |
2.57 Å |
RNAP |
RNAP (NS5B) |
CAQ(CATECHOL) |
| 4RY4 |
XRD |
Virus |
Hepatitis C virus(HCV) |
C-terminal mutant (Y448F) of HCV/j4 RNAP |
25428878 |
2.59 Å |
RNAP |
HCV J4 RNAP (NS5B) |
|
| 4RY5 |
XRD |
Virus |
Hepatitis C virus(HCV) |
C-terminal mutant (W550N) of HCV/J4 RNAP |
25428878 |
2.71 Å |
RNAP |
HCV J4 RNAP (NS5B) |
UTP[ URIDINE 5'-TRIPHOSPHATE ], MN |
| 4RY6 |
XRD |
Virus |
Hepatitis C virus(HCV) |
C-terminal mutant (W550A) of HCV/J4 RNAP |
25428878 |
2.52 Å |
RNAP |
HCV J4 RNAP (NS5B) |
|
| 4RY7 |
XRD |
Virus |
Hepatitis C virus(HCV) |
C-terminal mutant (D559E) of HCV/J4 RNAP |
25428878 |
3.00 Å |
RNAP |
HCV J4 RNAP (NS5B) |
|
| 5CZB |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B in complex with ligand Idx17119-5 |
27520942 |
1.96 Å |
RNAP |
RNAP (NS5B) |
55W[ 1-[4-(7-amino-5-methylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl]-3-{[(R)-(2,4-dimethylphenyl)(methoxy)phosphoryl]amino}-1H-pyrazole-4-carboxylic acid ] , MES[ 2-(N-MORPHOLINO)-ETHANESULFONIC ACID ], PEG[ DI(HYDROXYETHYL)ETHER ], SO4, GOL |
| 2XI3 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-h77 NS5B polymerase complexed with GTP |
20729191 |
1.70 Å |
RNAP |
RNAP (NS5B) |
GTP[ Guanosine-5'-Triphosphate ], MG |
| 2D3U |
XRD |
Virus |
Hepatitis C virus(HCV) |
X-ray crystal structure of hepatitis C virus RNAP in complex with non-nucleoside analogue inhibitor |
16828488 |
2.00 Å |
RNAP |
RNAP (NS5B) |
CCT[ 5-(4-CYANOPHENYL)-3-{[(2-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID ] |
| 2D3Z |
XRD |
Virus |
Hepatitis C virus(HCV) |
X-ray crystal structure of hepatitis C virus RNAP in complex with non-nucleoside analogue inhibitor |
16828488 |
1.80 Å |
RNAP |
RNAP (NS5B) |
FIH[ 5-(4-FLUOROPHENYL)-3-{[(4-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID ] |
| 2D41 |
XRD |
Virus |
Hepatitis C virus(HCV) |
X-ray crystal structure of hepatitis C virus RNAP in complex with non-nucleoside inhibitor |
16828488 |
2.10 Å |
RNAP |
RNAP (NS5B) |
SNH[ 5'-ACETYL-4-{[(2,4-DIMETHYLPHENYL)SULFONYL]AMINO}-2,2'-BITHIOPHENE-5-CARBOXYLIC ACID ] |
| 2FVC |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of NS5B BK strain (delta 24) in complex with a 3-(1,1-dioxo-2h-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1h)-quinolinone |
16451063 |
2.00 Å |
RNAP |
RNAP (NS5B) |
888[ 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one ] |
| 2GC8 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structure of a proline sulfonamide inhibitor bound to HCV NS5B polymerase |
16722622 |
2.20 Å |
RNAP |
RNAP (NS5B) |
885[ 1-[(2-AMINO-4-CHLORO-5-METHYLPHENYL)SULFONYL]-L-PROLINE ] |
| 2IJN |
XRD |
Virus |
Hepatitis C virus(HCV) |
Isothiazoles as activE-site inhibitors of HCV NS5B polymerase |
17049853 |
2.20 Å |
RNAP |
RNAP (NS5B) |
221[ (2R,3R)-3-{[3,5-BIS(TRIFLUOROMETHYL)PHENYL]AMINO}-2-CYANO-3-THIOXOPROPANAMIDE ] |
| 2QE2 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structure of HCV NS5B bound to an anthranilic acid inhibitor |
17402724 |
2.90 Å |
RNAP |
RNAP (NS5B) |
452[ 2-{[N-(2-ACETYL-5-CHLORO-4-FLUOROPHENYL)GLYCYL]AMINO}BENZOIC ACID ] |
| 2QE5 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structure of HCV NS5B bound to an anthranilic acid inhibitor |
17402724 |
2.60 Å |
RNAP |
RNAP (NS5B) |
617[ 2-{[(4-CHLOROPHENOXY)ACETYL]AMINO}BENZOIC ACID ] |
| 3HHK |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B polymerase complex with a substituted benzothiadizine |
19515564 |
1.70 Å |
RNAP |
RNAP (NS5B) |
77Z[ 2-({(3R)-3-[(3S)-1-(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydroquinolin-3-yl]-1,1-dioxido-3,4-dihydro-2H-1,2,4-benzothiadiazin-7-yl}oxy)acetamide ] |
| 6MVK |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B 1b n316 bound to compound 18 |
30763090 |
2.30 Å |
RNAP |
RNAP (NS5B) |
K4J[ (4-{(4S)-3-[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl]-2-oxo-1,3-oxazolidin-4-yl}-2-fluorophenyl)boronic acid ] |
| 6MVQ |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B 1b n316 bound to compound 31 |
30763090 |
2.14 Å |
RNAP |
RNAP (NS5B) |
K4M[(4-{1-[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl]-1H-1,2,4-triazol-5-yl}-2-fluorophenyl)boronic acid] |
| 3HKW |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B genotype 1a in complex with 1,5 benzodiazepine inhibitor 6 |
20071590 |
1.55 Å |
RNAP |
RNAP (NS5B) |
IX6[(11S)-10-[(2,5-dimethyl-1,3-oxazol-4-yl)carbonyl]-11-{2-fluoro-4-[(2-methylprop-2-en-1-yl)oxy]phenyl}-3,3-dimethyl-2,3,4,5,10,11-hexahydrothiopyrano[3,2-b][1,5]benzodiazepin-6-ol 1,1-dioxide] , SO4, GOL |
| 3QGH |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP genotype 1a complex with N-cyclopropyl-6-[(3r)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide |
21441029 |
2.14 Å |
RNAP |
RNAP (NS5B) |
63F[N-cyclopropyl-6-[(3R)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide] , PO4 |
| 3QGI |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP genotype 1a complex with N-[(2s)-butan-2-yl]-6-[(3r)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide |
21441029 |
1.80 Å |
RNAP |
RNAP (NS5B) |
33F[N-[(2S)-butan-2-yl]-6-[(3R)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide] , GOL |
| 6MVO |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B 1a y316 bound to compound 49 |
30763090 |
1.95 Å |
RNAP |
RNAP (NS5B) |
K4P[6-[(7-chloro-1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)(methylsulfonyl)amino]-5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide] , SO4 |
| 4KHM |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B GT1A with gsk5852 |
23672667 |
1.70 Å |
RNAP |
RNAP (NS5B) |
1PV[[4-({[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl](methylsulfonyl)amino}methyl)-2-fluorophenyl]boronic acid] , SO4 |
| 4KHR |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B GT1A c316y with gsk5852 |
23672667 |
2.45 Å |
RNAP |
RNAP (NS5B) |
1PV[[4-({[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl](methylsulfonyl)amino}methyl)-2-fluorophenyl]boronic acid] , SO4 |
| 3PHE |
EM |
Virus |
Hepatitis C virus(HCV) |
HCV NS5B with a bound quinolone inhibitor |
21145235 |
2.20 Å |
RNAP |
RNAP (NS5B) |
C9A[4-chlorobenzyl 6-fluoro-7-(4-methylpiperazin-1-yl)-1-[4-(methylsulfonyl)benzyl]-4-oxo-1,4-dihydroquinoline-3-carboxylate] |
| 4TXS |
EM |
Virus |
Hepatitis C virus(HCV) |
An ligand-observed mass spectrometry-based approach integrated into the fragment based lead discovery pipeline |
25666181 |
2.78 Å |
RNAP |
RNAP (NS5B) |
3AQ[(4-hydroxyphenyl)acetonitrile] |
| 4TY8 |
XRD |
Virus |
Hepatitis C virus(HCV) |
An ligand-observed mass spectrometry-based approach integrated into the fragment based lead discovery pipeline |
25666181 |
2.78 Å |
RNAP |
RNAP (NS5B) |
3AV[6-methyl-2H-chromen-2-one] |
| 4TY9 |
XRD |
Virus |
Hepatitis C virus(HCV) |
An ligand-observed mass spectrometry-based approach integrated into the fragment based lead discovery pipeline |
25666181 |
2.78 Å |
RNAP |
RNAP (NS5B) |
3B0[5-(trifluoromethyl)pyridin-2-amine] |
| 4TYA |
XRD |
Virus |
Hepatitis C virus(HCV) |
An ligand-observed mass spectrometry-based approach integrated into the fragment based lead discovery pipeline |
25666181 |
2.94 Å |
RNAP |
RNAP (NS5B) |
3AE[4-(trifluoromethyl)benzoic acid] |
| 1YUY |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus NS5B RNAP genotype 2A |
15746101 |
1.90 Å |
RNAP |
RNAP (NS5B) |
SO4 |
| 1YV2 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus NS5B RNAP genotype 2A |
15746101 |
2.50 Å |
RNAP |
RNAP (NS5B) |
SO4, GOL |
| 1YVX |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus RNAP genotype 2A in complex with non- nucleoside analogue inhibitor |
15746101 |
2.00 Å |
RNAP |
RNAP (NS5B) |
IPC[3-[ISOPROPYL(4-METHYLBENZOYL)AMINO]-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID] , SO4 |
| 1YVZ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus RNAP genotype 2A in complex with non- nucleoside analogue inhibitor |
15746101 |
2.20 Å |
RNAP |
RNAP (NS5B) |
JPC[3-[(2,4-DICHLOROBENZOYL)(ISOPROPYL)AMINO]-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID] , SO4 |
| 2XWH |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-j6 NS5B polymerase structure at 1.8 angstrom |
21209117 |
1.80 Å |
RNAP |
RNAP (NS5B) |
15P[POLYETHYLENE GLYCOL (N=34)], PEG[ DI(HYDROXYETHYL)ETHER ] |
| 4ADP |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-j6 NS5B polymerase V405I mutant |
22532694 |
1.90 Å |
RNAP |
RNAP (NS5B) |
|
| 3Q0Z |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP complex with (2e)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5h-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid |
21486696 |
2.29 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , SO4 |
| 3QGD |
EM |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP complex with (2e)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5h-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2r)-4-(2,6-dimethoxypyrimidin-4-yl)-1-[(4-ethylphenyl)sulfonyl]-N-(4-methoxybenzyl)piperazine-2-carboxamide |
21441029 |
2.60 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 26S[(2R)-4-(2,6-dimethoxypyrimidin-4-yl)-1-[(4-ethylphenyl)sulfonyl]-N-(4-methoxybenzyl)p |
| 3QGE |
EM |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP complex with (2e)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5h-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2r)-4-(2,6-dimethoxypyrimidin-4-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazine-2-carboxamide |
21441029 |
3.00 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 26F[(2R)-4-(2,6-dimethoxypyrimidin-4-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phen |
| 3QGF |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP complex with (2e)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5h-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2r)-4-(6-chloropyridazin-3-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazine-2-carboxamide |
21441029 |
2.45 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 46F[(2R)-4-(6-chloropyridazin-3-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phenyl]su |
| 3QGG |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP complex with (2e)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5h-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and N-cyclopropyl-6-[(3r)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide |
21441029 |
3.22 Å |
RNAP |
RNAP (NS5B) |
63F[N-cyclopropyl-6-[(3R)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide] , 23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl |
| 4NLD |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP complex with bms-791325 also known as (1ar,12bs)-8-cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-{[(1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl}-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide and 2-(4-fluorophenyl)-N-methyl-6-[(methylsulfonyl)amino]-5-(propan-2-yloxy)-1-benzofuran-3-carboxamide |
24397558 |
2.75 Å |
RNAP |
RNAP (NS5B) |
2N7[(1aR,12bS)-8-cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-{[(1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl}-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide] , 2N5[2-(4-fluorophenyl)-N-methyl-6-[(methylsulfonyl |
| 5PZK |
EM |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP in complex with 2-(4-fluorophenyl)-N-methyl-6-[(methylsulfonyl)amino]-5-(propan-2-yloxy)-1-benzofuran-3-carboxamide |
28430437 |
2.20 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 2N5[2-(4-fluorophenyl)-N-methyl-6-[(methylsulfonyl)amino]-5-(propan-2-yloxy)-1-benzofuran |
| 5PZL |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP in complex with 2-({3-[1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]-1,1-dioxo-1,4-dihydro-1lambda~6~,2,4-benzothiadiazin-7-yl}oxy)acetamide |
28430437 |
2.06 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 8XV[2-({3-[1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]-1,1- |
| 5PZM |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP in complex with 3-[2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-5-yl]benzoic acid |
28430437 |
2.54 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 8XS[3-[2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-5-yl]benzoic acid] , GOL,SO4 |
| 5PZN |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP in complex with 5-[3-(tert-butylcarbamoyl)phenyl]-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide |
28430437 |
2.25 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 8XP[5-[3-(tert-butylcarbamoyl)phenyl]-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxam |
| 5PZO |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP c316n in complex with 2-(4-fluorophenyl)-N-methyl-5-[3-({2-methyl-1-oxo-1-[(1,3,4-thiadiazol-2-yl)amino]propan-2-yl}carbamoyl)phenyl]-1-benzofuran-3-carboxamide |
28430437 |
2.80 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 8XM[2-(4-fluorophenyl)-N-methyl-5-[3-({2-methyl-1-oxo-1-[(1,3,4-thiadiazol-2-yl)amino]pro |
| 5PZP |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP in complex with 4-fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-{[1-(pyrimidin-2-yl)cyclopropyl]carbamoyl}phenyl)-1-benzofuran-3-carboxamide (bms-929075) |
28430437 |
2.95 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 8XJ[4-fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-{[1-(pyrimidin-2-yl)cyclopropyl]ca |
| 5TRH |
EM |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP in complex with 2-[(benzenecarbonyl)amino]-3-[(4-chlorophenyl)methoxy]benzoic acid |
27908764 |
2.70 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 7HL[2-[(benzenecarbonyl)amino]-3-[(4-chlorophenyl)methoxy]benzoic acid] , SO4 |
| 5TRI |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP in complex with 3-[(4-chlorophenyl)methoxy]-2-(1-oxo-1,3-dihydro-2h-isoindol-2-yl)benzoic acid |
27908764 |
2.30 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 7HM[3-[(4-chlorophenyl)methoxy]-2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)benzoic acid] ,SO4 |
| 5TRJ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNAP in complex with 2-{[2-(carboxymethoxy)benzene-1-carbonyl]amino}-3-[(4-chlorophenyl)methoxy]benzoic acid |
27908764 |
2.57 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 7HO[2-{[2-(carboxymethoxy)benzene-1-carbonyl]amino}-3-[(4-chlorophenyl)methoxy]benzoic ac |
| 5TRK |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNA- dependent RNAP in complex with N-{3-[(benzenecarbonyl)amino]-4-[(4-chlorophenyl)methoxy]benzene-1-carbonyl}glycine |
27908764 |
2.06 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 7HH[N-{3-[(benzenecarbonyl)amino]-4-[(4-chlorophenyl)methoxy]benzene-1-carbonyl}glycine] |
| 5TWN |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of the hepatitis C virus NS5B RNA- dependent RNAP in complex with 5-[3-(tert-butylcarbamoyl)phenyl]-6-(ethylamino)-2-(4-fluorophenyl)-N-methylfuro[2,3-b]pyridine-3-carboxamide |
30108798 |
3.04 Å |
RNAP |
RNAP (NS5B) |
23E[(2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid] , 7NG[ 5-[3-(tert-butylcarbamoyl)phenyl]-6-(ethylamino)-2-(4-fluorophenyl)-N-methylfuro[2, |
| 3FQQ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of a novel dimeric form of HCV NS5A domain L protein |
19244328 |
2.20 Å |
Subunit |
Non-Structural Protein 5a |
0BD[3-methyl-1-(2-methylpropyl)butyl 4-O-beta-L-gulopyranosyl-beta-D-glucopyranoside], GOL, ZN |
| 1ZH1 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structure of the zinc-binding domain of HCV NS5A |
15902263 |
2.50 Å |
Subunit |
Non-Structural Polyprotein |
ZN |
| 3FQL |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B (con1 1-570) with HCV-796 inhibitor |
19246450 |
1.80 Å |
RNAP |
RNAP |
79Z[5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide] , GOL |
| 3FQM |
XRD |
Virus |
Hepatitis C virus(HCV) |
Crystal structure of a novel dimeric form of HCV NS5A domain L protein |
19244328 |
1.90 Å |
Subunit |
Non-Structural Protein 5a |
GOL, ZN |
| 6GP9 |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structural studies of hepatitis C virus non-structural protein-5b of genotype 4a |
|
3.10 Å |
RNAP |
RNAP (NS5B) |
|
| 3HVO |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structure of the genotype 2b HCV polymerase bound to a nni |
To be published. |
2.00 Å |
RNAP |
RNAP (NS5B) |
VGI[2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino]-1h-benzo[de]isoquinoline-1,3(2h)-dione] |
| 3GSZ |
XRD |
Virus |
Hepatitis C virus(HCV) |
Structure of the genotype 2b HCV polymerase |
19505479 |
1.90 Å |
RNAP |
RNAP (NS5B) |
|
| 4CL1 |
XRD |
Virus |
Hepatitis C virus(HCV) |
The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors |
24639329 |
3.50 Å |
Subunit |
Non-Structural Protein 5a |
3K1??5-hydroxy-2-??4-(1H-tetrazol-5-yl)phenyl??pyrimidin-4(3H)-one?? SO4 MN |
| 2XI2 |
XRD |
Virus |
Hepatitis C virus(HCV) |
HCV-H77 NS5B apo polymerase |
20729191 |
1.80 Å |
RNAP |
RNAP (NS5B) |
SO4 |
| 6W4G |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus polymerase NS5B with ro inhibitor for sar studies |
33085891 |
1.95 Å |
RNAP |
RNAP (NS5B) |
SL4??5-[[(2~{S})-4-[1,1-bis(oxidanylidene)-1,2-benzothiazol-3-yl]-2-~{tert}-butyl-3-oxidanyl-5-oxidanylidene-2~{H}-pyrrol-1-yl]methyl]-2-fluoranyl-benzenecarbonitrile?? |
| 1YVF |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus NS5B RNAP complex with inhibitor pha-00729145 |
15863301 |
2.50 Å |
RNAP |
RNAP (NS5B) |
PH7??(2Z)-2-(BENZOYLAMINO)-3-[4-(2-BROMOPHENOXY)PHENYL]-2-PROPENOIC ACID?? PO4 GOL??GLYCEROL?? CL |
| 1Z4U |
XRD |
Virus |
Hepatitis C virus(HCV) |
Hepatitis C virus NS5B RNAP complex with inhibitor pha-00799585 |
15911260 |
2.80 Å |
RNAP |
RNAP (NS5B) |
PH9??(2Z)-2-??(1-ADAMANTYLCARBONYL)AMINO??-3-??4-(2-BROMOPHENOXY)PHENYL??PROP-2-ENOIC ACID?? PO4 GOL CL |
| 2M5L |
XRD |
Virus |
Hepatitis C virus(HCV) |
NS5A308 |
To be published. |
|
Subunit |
NS5A Protein |
|
| 4TLR |
XRD |
Virus |
Hepatitis C virus(HCV) |
NS5B in complex with lactam-thiophene carboxylic acids |
24986660 |
1.86 Å |
RNAP |
RNAP (NS5B) |
33H??3-{(2R,5R)-5-cyclohexyl-2-[(2R)-2-hydroxypropyl]-3-oxomorpholin-4-yl}-5-(3,3-dimethylbut-1-yn-1-yl)thiophene-2-carboxylic acid?? 79Z??5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide?? |